DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
회사 코드DXCM
회사 이름Dexcom Inc
상장일Apr 14, 2005
설립일1999
CEOMr. Kevin R. Sayer
직원 수10300
유형Ordinary Share
회계 연도 종료Apr 14
주소6340 Sequence Dr
도시SAN DIEGO
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호92121
전화18582000200
웹사이트https://www.dexcom.com/
회사 코드DXCM
상장일Apr 14, 2005
설립일1999
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음